press-release/
25 pages · Updated September 7, 2026
Pages
- Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
- Ipsen presents strong full-year 2021 results and enters into exclusive negotiations to divest its Consumer Healthcare business
- Ipsen and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders
- Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
- Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio
- Ipsen to acquire exclusive rights to investigational ERK inhibitor as part of its existing research collaboration with AGV Discovery
- Ipsen completes acquisition of Epizyme expanding its portfolio in oncology
- Ipsen and Marengo Therapeutics announce strategic partnership to advance two precision immuno-oncology candidates from Marengo’s STAR Platform into the clinic
- Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline
- Acquisition of Albireo has been completed | Ipsen Global
- Ipsen and Blueprint Medicines announce exclusive global license agreement to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva (FOP)
- Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance
- Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson’s disease
- Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
- Exclusive Licensing Agreement with GENFIT | Ipsen Global
- Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
- Ipsen adds another program into its pre-clinical R&D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3
- Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity
- Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
- Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
- Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.
- Ipsen updates on QM-1114 regulatory process
- Ipsen S.A. publishes its 2026 Half-Year Report (half-year ended 30 June 2026)
- Ipsen to Acquire Epizyme - Growth in Oncology | Ipsen Global
- Ipsen to Acquire Albireo - Growth in Rare Disease | Ipsen Global